tretinoin + thioglycollate

The name **tretinoin + thioglycollate** appears to be an erroneous transcription or misidentification of the combination of **triamcinolone acetonide and sucralfate**, as evidenced by the associated clinical trial registry ID **ChiCTR2200066181**. The actual study, sponsored by Hainan Hospital and Ruijin Hospital, evaluates the efficacy of a gel filling containing triamcinolone acetonide (a potent corticosteroid) and sucralfate (a mucosal protective agent) for the prevention of esophageal stricture following large-area endoscopic submucosal dissection (ESD). Triamcinolone acts by inhibiting the inflammatory response and reducing collagen synthesis to prevent fibrosis, while sucralfate provides a physical barrier over the injured esophageal mucosa to promote healing. Tretinoin is a retinoid typically used for acne or leukemia, and thioglycollate is a chemical reducing agent used in depilatories or culture media; neither is standardly used in this therapeutic context.

Other names

trimethoprim + thioglycollate